HXN-1031
/ Earendil Labs
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 10, 2026
Development of a novel anti-CD19 x BCMA dual targeted T cell engager for the treatment of autoimmune diseases and B cell malignancies
(AAAAI 2026)
- "In vivo, twice-weekly HXN-1031 demonstrated superior efficacy to Blinatumomab against CD19+ tumors, and significantly suppressed BCMA+ tumor growth, matching Teclistamab analogue efficacy. Conclusions HXN-1031 is an innovative TCE with finely tuned activity, designed to reset immune system by simultaneously depleting pathogenic B cells and plasma cells. It holds great potential in the treatment of various B cell and plasma cell related autoimmune diseases and malignancies."
Hematological Malignancies • Immunology • Oncology
1 to 1
Of
1
Go to page
1